Samsung Medical Center
| Republik Korea | Türkei | Österreich | |
| Knochenmarktransplantation | von $55,000 | von $36,000 | von $140,000 |
| Chemotherapie bei Brustkrebs | von $19,200 | von $1,200 | von $15,000 |
| Autologe Knochenmarktransplantation | von $42,000 | von $31,500 | von $50,000 |
| Allogene Knochenmarktransplantation von einem verwandten Spender | von $75,000 | von $65,000 | von $150,000 |
| Allogene Knochenmarktransplantation von einem nicht verwandten Spender | von $145,000 | von $80,000 | von $180,000 |
Bookimed erhebt keine zusätzlichen Gebühren für Akute lymphatische Leukämie-Behandlungspreise. Die Preise stammen aus den offiziellen Preislisten der Kliniken. Sie zahlen direkt in der Klinik für Ihre Behandlung bei Ihrer Ankunft im Land.
Bookimed setzt sich für Ihre Sicherheit ein. Wir arbeiten nur mit medizinischen Einrichtungen zusammen, die hohe internationale Standards bei der Behandlung von Akute lymphatische Leukämie einhalten und über die notwendigen Lizenzen verfügen, um internationale Patienten weltweit zu behandeln.
Bookimed bietet kostenlose fachliche Unterstützung. Ein persönlicher medizinischer Koordinator unterstützt Sie vor, während und nach Ihrer Behandlung und hilft Ihnen bei allen Fragen. Sie sind auf Ihrer Akute lymphatische Leukämie-Behandlungsreise nie allein.
South Korea offers comprehensive acute lymphoblastic leukemia care at Joint Commission International-accredited tertiary centers. Treatment includes multi-phase chemotherapy, minimal residual disease monitoring, and hematopoietic stem cell transplantation. Specialized facilities provide advanced immunotherapies like CAR-T cell therapy and targeted agents for Philadelphia chromosome-positive cases.
Bookimed Expert Insight: South Korea is home to the first digital hospital in the country, Seoul National University Bundang Hospital. This digitalization ensures rapid data processing and treatment initiation. Major centers like Asan Medical Center perform over 65,000 operations yearly. High patient volumes allow these hospitals to maintain specialized teams for complex infection control during induction chemotherapy.
Patient Consensus: Patients note that treatment intensity is high. They emphasize the importance of choosing large university hospitals to ensure access to superior infection management and blood transfusion support.
Patients in South Korea undergo risk stratification using molecular subtyping and minimal residual disease (MRD) monitoring. Doctors categorize cases by age, genetic mutations, and early treatment response. JCI-accredited facilities like Severance Hospital then tailor chemo-intensity and bone marrow transplant protocols to individual genetic profiles.
Bookimed Expert Insight: Clinical data from Seoul National University Hospital shows that digitalization drives South Korea's high success rates. Their fully digital systems prevent errors by tracking real-time lab adjustments. Clinics like Asan Medical Center perform over 65,000 operations annually, allowing teams to refine risk-stratified pathways through immense patient volumes.
Patient Consensus: Patients note that risk is re-checked throughout treatment rather than decided once. They emphasize that genetic results often change their category and influence transplant decisions.
Seoul's major tertiary centers are globally recognized for acute lymphoblastic leukemia (ALL) care. Asan Medical Center, Samsung Medical Center, and Seoul National University Hospital lead in outcomes. These JCI-accredited facilities provide advanced bone marrow transplants and intensive chemotherapy for complex hematologic cases.
Bookimed Expert Insight: Patient volume is a primary indicator of leukemia expertise in South Korea. Hospitals like Samsung Medical Center serve over 2,000,000 patients annually. This massive scale allows hematology teams to manage rare ALL subtypes effectively. Large centers also provide critical 24-hour ICU support mandatory for intensive induction therapy.
Patient Consensus: Patients emphasize that for ALL, choosing a hospital with high-volume transplant capacity is essential. Many travelers prioritize Seoul-based centers because they offer rapid molecular testing and specialized infection-management protocols.
South Korean oncology centers balance pediatric acute lymphoblastic leukemia (ALL) cures with quality of life. They use risk-adapted strategies to achieve 92% survival rates. Doctors adjust treatment intensity using minimal residual disease monitoring. This tailored approach minimizes toxicities like cardiotoxicity and cognitive impairment in standard-risk children.
Bookimed Expert Insight: Quality of life is prioritized through massive institutional scale and digital precision. Severance Hospital treats 4,000,000 patients annually and holds JCI accreditation for safety. Large centers like Asan Medical Center perform over 65,000 surgeries yearly. This high volume allows Korean specialists to refine protocols that reduce long-term side effects while maintaining top-tier outcomes.
Patient Consensus: Parents note that treatment is highly structured with family involvement in safety decisions. Families often weigh avoiding late effects against relapse risk to protect a child's future learning ability.
International patients can access novel leukemia therapies in South Korea through major university hospitals. South Korea ranks among the top 10 global trial locations. Over 200 certified centers provide streamlined 30-day trial approvals. Most international participation occurs during phase II or III global clinical studies.
Bookimed Expert Insight: While South Korea excels in research, trial eligibility for non-residents is often stricter than standard treatment. Asan Medical Center serves over 180,000 patients annually and handles 45% of Korea's heart transplants. This massive clinical volume allows their teams to manage complex Acute Lymphoblastic Leukemia cases that other regions might decline.
Patient Consensus: Patients note that language barriers and intensive paperwork are often bigger hurdles than the medical treatment itself. They recommend preparing full English records, specifically genetic results and prior therapy history, before requesting a trial evaluation.